• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

370
62
45
43
20

COUNTRY

42
10
5
5
4

PRICE

136
413
513
1,035

PUBLISHED

24
68
291
1,035

PRODUCT TYPE

1,002
17
11
4
1

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

PharmaPoint: Schizophrenia - Current and Future Players

PharmaPoint: Schizophrenia - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Schizophrenia - Current and Future Players”. The report is a vital source of...

February 2014
FROM

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as one...

February 2014
FROM

EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023 Summary Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following...

February 2014
FROM

Mental Health and Work: United Kingdom

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

February 2014
FROM

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic...

January 2014
FROM

Batten Disease - Pipeline Review, H1 2014

Batten Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Batten Disease - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides...

January 2014
FROM

Mental Health and Work: Switzerland

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

January 2014
FROM

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Progressive Supranuclear Palsy - Pipeline Review, H2 2013

Progressive Supranuclear Palsy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Progressive Supranuclear Palsy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2013', provides an overview of the...

December 2013
FROM

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review,...

December 2013
FROM

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM

Degenerative Disc Disease - Pipeline Review, H2 2013

Degenerative Disc Disease - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Degenerative Disc Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

Hyperalgesia - Pipeline Review, H2 2013

Hyperalgesia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hyperalgesia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Tauopathies - Pipeline Review, H2 2013

Tauopathies - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Tauopathies - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

General Anxiety Disorder - Pipeline Review, H2 2013

General Anxiety Disorder - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'General Anxiety Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

Peripheral Neuropathic Pain - Pipeline Review, H2 2013

Peripheral Neuropathic Pain - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Child Abuse Global Clinical Trials Review, H2, 2013

Child Abuse Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Child Abuse Global Clinical Trials Review, H2, 2013" provides data on the Child Abuse clinical trial scenario....

December 2013
FROM
Loading Indicator

Our Clients

Our clients' logos